EVALUATION OF ONCOLOGY DRUG AVAILABILITY IN STATE MEDICAID FORMULARIES

Author(s)

Neugebauer K1, Austin JM1, Hooper M1, Kazempour esmati A1, Richard R2, Rosenthal S1, Sheffield S1, Wu S1, Lal L3
1Rice University, Houston, TX, USA, 2Rice University, Spring, TX, USA, 3Optum, Missouri City, TX, USA

OBJECTIVES: Medicaid traditionally provided free or low-cost health insurance coverage to low-income families and children, pregnant women, elderly, and people with disabilities. With the passage of Affordable Care Act, Medicaid expanded in some states to insure low income single adults. As of September, 2018, 17 states have not expanded Medicaid, while 33 states have expanded. This study was conducted to determine the availability of oral oncology products approved since 2010, on the Medicaid formularies and compare the availability between expanded and non-expanded states.

METHODS: Newly approved oral oncology products by the Food and Drug Administration (FDA) from 2010 to 2017 were identified and then searched for on the Medicaid 2018 formularies for all 50 states. Products were classified as available on the formularies, even if the drug required prior authorization or appeal process to acquire. Descriptive statistics and Z- test were utilized to analyze the results.

RESULTS:A total of 44 drugs were identified as oral oncology products approved between 2010 and 2017. Twenty- three states did not cover any of these products, of which seven (7/23 (30%)) have not expanded Medicaid and 16 have expanded Medicaid (16/23 (70%)). Overall, the average number of oral products were 15 in the expanded states and 14 in the non-expanded states (p=0.86). Limiting to only states with formulary inclusion, the average number of covered products were 30 in the expanded states versus 27 in the non-expanded states (p=0.68).

CONCLUSIONS: Even with increased access to healthcare through Medicaid expansion, significant gaps in coverage for oral oncology products continue to exist in the state Medicaid formularies. Policies addressing coverage decisions would need to be created to address these challenges.

Conference/Value in Health Info

2019-05, ISPOR 2019, New Orleans, LA, USA

Value in Health, Volume 22, Issue S1 (2019 May)

Code

PCN194

Topic

Health Policy & Regulatory

Topic Subcategory

Health Disparities & Equity

Disease

Drugs

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×